NecstGen

We are proud to share that our recurrent customer Pan Cancer T secured € 4.25 million seed extension and continues its path to the clinic to treat solid tumors! Press release: Rotterdam and Leiden, Netherlands, July 17, 2024 – NecstGen, a non-profit CDMO, and Pan Cancer T, a company developing a TCR-T cell product (PCT1:CO-STIM) for the treatment of triple negative breast cancer, announce further projects.   This new agreement with Pan Cancer T builds directly on the solid foundation established in previous collaborations between both organisations. Following a successful technology transfer and proof-of-concept scale-up, both parties are happy to announce that more activities will be performed by NecstGen at its state-of-the-art facility for Cell and Gene Therapy development and manufacturing located in Leiden.   Rachel Abbott, CEO, Pan Cancer T commented, “Successfully completing our latest funding round will accelerate our path to the clinic and treating patients. CMC development is a critical component to realising this ambition. We recognise in NecstGen a partner committed to reducing the costs of development and manufacturing whilst maintaining commitment to quality.”   The companies will continue to undertake the process and analytical development of Pan Cancer T’s novel Cell Therapy. Led by Melissa Van Pel, Head of Cell Therapy, NecstGen will utilise its large equipment portfolio and expert team to progress the process and assays required for PCT1:CO-STIM to be successfully manufactured.   This continued collaboration demonstrates NecstGen’s capability to scale and enhance processes as its partnerships evolve to enable bridging early research and clinical applications, including GMP manufacturing.    Paul Bilars, CEO, NecstGen, said, “I am delighted with my team’s performance in our partnership with Pan Cancer T to date, demonstrating what NecstGen can contribute to organisations in Cell and Gene Therapy. NecstGen now routinely receives feedback that we are offering partners a competitive cost basis. This is core to our vision as an organisation. Maximising the budget of all organisations involved in Cell and Gene Therapy will accelerate therapies reaching patients and benefiting society.” Full press release: https://lnkd.in/eYpnTgRX For more information please contact:   Pan Cancer T - Rachel Abbott, CEO NecstGen - Tristan Pritchard-Meaker, Head of Business Development

We're #hiring a new Technician Viral Vector in Leiden, South Holland. Apply today or share this post with your network.

We're #hiring a new Maintenance Technician – permanent and temporary position. in Leiden, South Holland. Apply today or share this post with your network.

A few days ago, our team, comprising Melissa Van Pel, David W., Yasmin Habani, Conor Vogelzang, and Tristan Pritchard-Meaker, visited bioMérieux in Lyon to strengthen our partnership further and explore the forefront of Cell and Gene Therapy (CGT). We explored current trends and developments within the CGT field during our visit. Additionally, we were given a tour of bioMérieux’s state-of-the-art specialist manufacturing facilities, where we observed their advanced processes firsthand! Our collaborative session on Quality Control (QC) applications in CGT was a significant highlight. We shared our feedback and user experiences, identified unmet needs in our field, and discussed the potential to further support and enhance QC processes. This exchange of ideas is crucial for pushing the boundaries of what’s possible in CGT. Melissa gave an insightful presentation on CGT/NecstGen projects, showcasing our ongoing initiatives and future goals. Her presentation underscored our commitment to innovation and excellence in the field. We look forward to our continued collaboration! #cellandgenetherapy #qualitycontrol #innovation #partnership #bioMérieux

We're #hiring a new Warehouse & Logistics Operator in Leiden, South Holland. Apply today or share this post with your network.

NecstGen is looking for passionate individuals to fill key positions in our Facilities and Services team. As part of our mission, you will not only support innovative cell and gene therapies but also become a co-author of our pioneering story in Regenerative Medicine. Please share this with anyone in your network who might be the perfect fit for our dynamic team! We're hiring for several roles, including Head of Facilities and Services, Maintenance Technician, Support Engineer (Summer), and a Warehouse Logistics Operator. In addition, we're offering an internship in Facilities and Services to work in an exciting facility with modern, state-of-the-art techniques. At NecstGen, you'll thrive in a supportive environment that values your well-being and professional development. More than a job, we offer you the chance to make a tangible impact on people's health and happiness. View and apply to our open vacancies on our website: https://lnkd.in/gXDv4YYh #hiring #facilities #services #technician #engineering

Today, we started with an inspiring presidential plenary session at the ISSCR 2024 Annual Meeting in Hamburg, Germany. This gathering brings together  4,000+ international scientists, making it a hub of innovation and collaboration in stem cell research and regenerative medicine. NecstGen is excited to attend this event and connect with innovators, exchange ideas, and stay at the forefront of scientific advancements. We're particularly looking forward to the diverse program, including plenary and concurrent sessions, science spotlights, and innovation showcases, which align perfectly with our mission to support and accelerate cutting-edge research. Join us at booth #702 to connect with our team members Tristan Pritchard-Meaker, Óscar Bártulos, André Soares, and Sophia Kolbe. Let's discuss how we can accelerate your projects and drive meaningful advancements together. #ISSCR2024 #stemcells #regenerativemedicine #celltherapy #genetherapy #CGT

NecstGen is proud to announce a collaboration with Dr. Debby Gawlitta of the Department of Oral and Maxillofacial Surgery & Special Dental Care at UMC Utrecht to develop an innovative bone regeneration therapy using mesenchymal stromal cell-derived spheroids. Dr. Gawlitta’s research has demonstrated promising results in preclinical studies, showcasing successful endochondral bone regeneration in rat and goat models. Through this collaboration, NecstGen will support Dr. Gawlitta’s project by offering development support of this innovative therapy. “We are excited about the potential of this collaboration with Dr. Gawlitta,” said Paul Bilars, CEO of NecstGen. “Our mission is to accelerate the delivery of innovative medicinal products to patients. This project exemplifies our commitment to support the next generation of therapies that can significantly impact patients’ lives.” Dr. Gawlitta has received a RegMed XB/Dutch Cardiovascular Alliance Thematic Tech Transfer Voucher sponsoring this collaborative activity to further develop her innovative findings into treatments. Read the full press release here: https://lnkd.in/ejWrqbCd

NecstGen team outing, an afternoon of fun and boating! Yesterday, our team gathered at Watersport Centrum Vlietland for a memorable summer event.   We kicked off with dragon boat races. Divided into teams, we paddled with all our might, striving for victory. These activities tested our teamwork, strategy, and quick thinking. Each team had a unique yell and colour, adding to the vibrant and competitive atmosphere. One of our favourite chants was from the orange team: "Row, row, orange crew, Victory's in sight, through and through!"   The spirit of friendly competition was alive as everyone gave their best effort. The water splashed, the boats surged, and the cheers echoed across the lake.   As the sun began to set, we gathered for a barbecue. The aroma of grilled food filled the air as we shared stories and laughed over delicious meals and drinks.   Here's to many more such memorable moments together as a team!   #necstgen #teamwork

Have you caught the latest news in Cell and Gene Therapies? Swipe through the carousel for an overview of recent advancements in this field, which includes:   Rare Blood Disorders – Hemophilia A 2seventy bio announces completion of asset purchase agreement by Novo Nordisk worth up to $40 million.  (https://lnkd.in/ezsrj5FU) Diabetes Enrollment for cohort 2 of Sernova's ongoing Phase I/II Clinical Trial for the treatment of Type I Diabetes (T1D) conducted at the University of Chicago has been completed. (https://lnkd.in/eF6Ey3rk) mRNA Genomic Medicines Exsilio Therapeutics announces $82 million Series A funding round to develop genomic medicines for a broad range of diseases, including cancer, genetic diseases, and autoimmune diseases. (https://lnkd.in/encjwrze) Neurological Disorders – Focal Refractory Epilepsy UCL spin-out EpilepsyGTx announced raise of $10 million seed round, which was led by UCL Technology Fund. (https://lnkd.in/ees86gay) Improved Prime Editing Systems Scientists at the Broad Institute of MIT and Harvard have improved a gene-editing technology capable of inserting or substituting entire genes in the genome in human cells efficiently enough to be potentially useful for therapeutic applications. (https://lnkd.in/eqQ7pyYr) FOXG1 Gene Therapy A viral gene therapy developed by University at Buffalo researchers has reversed some brain abnormalities in infant mice with FOXG1 syndrome, a significant step toward one day treating children with this severe neurodevelopmental disorder. (https://lnkd.in/e_aeWqZz.) Mole reversal therapy Researchers at the The Francis Crick Institute, UCL Great Ormond Street Institute for Child Health and Great Ormond Street Hospital for Children (GOSH) have designed a new genetic therapy that could alleviate debilitating giant moles in a rare skin condition. (https://lnkd.in/eQrTsWSq) These news items are chapters that shape the story of how cell and gene therapies (CGTs) bring life-saving treatments to patients, transforming the landscape of medical care. Do you want more news like this delivered directly to your feed? Stay informed and engaged with the latest developments by following us. #celltherapy #genetherapy #CGTs #atmps